An abdominal aortic aneurysm (AAA) is a local “ballooning” of the aorta – the biggest blood vessel in the human body.
AAA is a frequent disease, affecting up to 5% of the population.
AAAs are progressive in nature – that means, AAAs become larger over time and may eventually rupture. AAA rupture is lethal in most cases.
To date, there is no treatment to stop AAA progression.
Angiolutions develops the world‘s first device to prevent small abdominal aortic aneurysm (AAA) progression and thereby revolutionizes the way AAA are treated today.
AAAs are focal dilations of the abdominal aorta that may grow and eventually rupture fatally. That’s why AAAs sometimes are called ticking time bombs.
While patients with large AAAs may receive prosthetic treatments to reduce the risk of imminent rupture, there presently is no therapy available for patients with small AAAs to prevent the life-threatening disease progression at a still relatively harmless stage.
Based on latest research findings, Angiolutions is pioneering the development of a first-of-its-kind minimally invasive device to prevent small AAAs progression, stop the ticking time bomb, and bring back peace of mind to thousands of patients.
Angiolutions’ leadership team: Co-founders and Co-CEOs Dr. Uwe Raaz & Dr. Isabel N. Schellinger and Chief Business Officer Marius Rummel. Together, they lead a diverse, interdisciplinary team that is complemented by a board of industry veterans, top clinicians and leading researchers.
receive update emails a few times a year
Please leave your message here